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ABSTRACT
Aim. The purpose of this study was to analyse the diagnostic value of gated myocardial perfusion imaging (G-MPI) in the eva-
luation of myocardial injury in sarcoglycanopathy.
Materials and methods. Twenty-eight patients diagnosed with sarcoglycanopathy were evaluated using 
99Tcm-methoxyisobutylisonitrile(99Tcm-MIBI) G-MPI. The data was processed into tomographic images, and the left ventricular function 
was analysed using quantitative gated SPECT (QGS) to assess the degree of impairment in myocardial and cardiac function.
Results. The images of 23 of the patients (82.1%) were positive. Two hundred and twenty-nine sub-segments with abnormal 
lesions were detected out of 391 cardiac sub-segments of these 23 positive cases. According to the segmental abnormalities, 
the cases were divided into two cases (8.7%) with single abnormal wall segment, six cases (26.1%) with two abnormal wall 
segments, and 15 cases (65.2%) with three or more abnormal wall segments or scattered lesions.
Conclusions. 99Tcm-MIBI G-MPI can objectively show impaired myocardium in patients with sarcoglycanopathy. Therefore, this 
method is helpful for early diagnosis and follow-up of myocardial damage.
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Introduction
Sarcoglycanopathy is the general term used to describe 
limb-girdle muscular dystrophy (LGMD) (2D, 2E, 2C, and 
2F), which is caused due to defects in the expression of the 
four subunits of myosin protein: α-, b-, g-, and d [1, 2]. The 
coding genes for α-, b-, g-, and d subunits of myosin protein are 
SGCA(17q21), SGCB(4q12), SGCG(13q12), and SGCD(5q33), 
respectively. LGMD refers to a group of hereditary skeletal 
muscle diseases with the main clinical manifestations being 
amyosthenia and progressive aggravated myatrophy in the 
proximal extremity and lumbar muscles [3–5]. Both the 
myocardium and the skeletal muscles belong to the striated 
muscle, and they are differentiated from the mesenchymal 
cells. The mesenchymal cells first differentiate into the myob-
lasts, and then differentiate into the myocytes and the skeletal 
muscle cells differently [6]. Due to these common histologic 
and embryologic features, genetic or metabolic diseases that 
affect the skeletal muscle fibres may cause myocardial dama-
ge by affecting the structure, function, or metabolism of the 
cardiac muscle cells.
At present, studies on cardiac injury in sarcoglycanopathy 
are mostly focused on electrocardiograms or echocardiograp-
hy. For example, ultrasound is used to measure the changes 
in thickness of the atrophied muscles [7], or to diagnose and 
evaluate the efficacy of myocardiac dystrophy [8]. The advan-
tage of magnetic resonance imaging (MRI) is that it can access 
the energy metabolism and function of the heart, which is 
important information about the early stages of myocardial 
damage in muscular dystrophy [9]. Radionuclide myocardial 
imaging can simultaneously display myocardial metabolism 
and blood flow distribution. It is also used in determining the 
existence of myocardial ischaemia as well as the ischaemic site 
and scope, detecting myocardial survival, and understanding 
the wall movement and the left ventricular function [10]. 
However, few studies have been conducted into applying 
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radionuclide myocardial imaging in evaluating myocardial 
damage in sarcoglycanopathy. 
In this study, 99Tcm-methoxyisobutylisonitrile (99Tcm-MIBI) 
gated myocardial perfusion imaging (G-MPI) was performed 
on 13 patients with myopathy (the CON group) and 28 patients 
with sarcoglycanopathy (the SAR group) diagnosed through 
clinical, routine pathological staining, and immunohisto-
chemical staining of muscle biopsy in our hospital. The aim 
was to analyse the value of gated myocardial tomography in 




Twenty-eight patients with sarcoglycanopathy diagnosed 
through clinical, routine pathological staining, and immuno-
histochemical staining of muscle biopsy in the Department 
of Neuromuscular Diseases of our hospital from Septem-
ber 2008 to July 2017 were enrolled in the study, including 
17 males and 11 females, aged 8–30 years, with an average 
age of 15.3 ± 4.1 years. The CON group was composed of 
13 patients, aged 16.5 ± 3.9 years. The diagnosis was based 
on the clinical manifestations of amyosthenia and progressive 
aggravated myatrophy in the proximal extremity muscles. All 
28 patients in the SAR group had different levels of elevated 
blood CK (366 to 8,270 IU/L) and exhibited myogenic injury 
in the electromyograms. All patients were further confirmed 
through skeletal muscle biopsy and immunohistochemical 
staining. The 13 patients in the CON group were collected 
from the Department of Neuromuscular Diseases and clini-
cally newly diagnosed with myopathy while excluding patients 
with sarcoglycanopathy, Duchenne, or Becker muscular dys-
trophy through skeletal muscle biopsy, immunohistochemical 
staining, and pathological analysis. Heart colour Doppler 
ultrasound and electrocardiogram examination revealed 
no abnormality in the heart. This study was conducted in 
accordance with the Declaration of Helsinki. This study was 
conducted with approval from the Ethics Committee of Hebei 
Medical University. Written informed consent was obtained 
from all participants.
Imaging data collection
Each studied subject was intravenously injected with 
111-740MBq 99Tcm-MIBI (99Tcm, HTA Co., Ltd; MIBI, Beijing 
Shihong Pharmaceutical Centre) (radiochemical purity > 
95%) in fasting and resting conditions. The dosing method 
was as follows: dosage = body weight (kg) / 70 × adult dose 
[11]. Thirty minutes later, 150–200 ml of milk was administe-
red, and gated myocardial perfusion imaging was performed 
1.5h later. The imaging apparatus used here was the Infinia 
VC Hawkeye dual-head single-photon emission-computed 
tomography (SPECT, GE, USA), together with a low-energy, 
high-resolution collimator. The acquisition conditions and 
methods were referred to the reference [11]. The electrocar-
diographic R-wave was used to trigger the gated synchronous 
acquisition (8 frames per cycle with the matrix as 64 × 64). 
Image analysis and processing were performed using the 
Xeleris functional imaging processing station (GE, USA); the 
image reconstruction used the filtered back projection method 
with Butterworth as the filter function and the system-recom-
mended cutoff frequency and steepness factor. Images of the 
short, vertical long and horizontal long axis were shown after 
reconstruction. Quantitative gated SPECT (QGS) software was 
used to analyse the left ventricular ejection fraction (LVEF), 
end-diastolic volume (EDV), and end-systolic volume (ESV).
Image processing and result analysis
The left ventricle is divided into seven segments (the car-
diac apex, anterior, anterolateral, inferolateral, inferior, inferior 
septum, and anterior septum wall) and 17 subsegments, inclu-
ding the cardiac apical, the proximal cardiac apical (anterior, 
septum, inferior, and lateral wall), the proximal basement 
(anterior, anterior interarticular, inferior interarticular, infe-
rior, inferolateral, and anterolateral wall), and the basement 
(anterior, anterior interarticular, inferior interarticular, 
inferior, inferolateral, and anterolateral wall) subsegments. 
In addition, the radioactivity of each segment was scored 
using one 5-point scoring method (i.e. from 0 to 4 points) as 
follows: 0 point = normal radioactivity distribution, 1 point = 
mild decreased uptake, 2 points = moderate decreased uptake, 
3 points = severe decreased uptake, 4 points = no radioactive 
uptake. According to the number of lesion-involved segments, 
mild lesions were limited to one segment, moderate lesions 
involved two segments, and severe lesions involved three 
segments. All the images were determined by two or more 
experienced nuclear medicine practitioners.
Results
Pathological analysis of skeletal muscle biopsy
Histochemical staining: All the 28 patients showed patho-
logical changes of muscular dystrophy, together with different 
sizes of muscular fibre, different degrees of muscular fibre 
necrosis and regeneration, scattered opaque muscle fibres, hy-
perplasia, degeneration necrosis of connective tissue, myofibre 
regeneration, and obvious connective tissue hyperplasia (Fig. 1).
The immunohistochemical staining of the skeletal muscle 
biopsies of the SAR group of 28 patients showed attenuation/
defects in the expression of α-, b-, g-, and d-sarcoglycan pro-
teins on the myofibril membranes (by immunohistochemical 
staining of anti-α-, b-, g-, and d-sarcoglycan monoclonal 
antibodies), as shown in Figure 2.
G-MPI
The results of 99Tcm-MIBI G-MPI in the CON group sho-
wed that the thickness of the myocardium of the left ventricle 
was uniform, and the radioactivity of each segment was evenly 
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Figure 1. Pathological changes of skeletal muscle biopsy: varying 
muscle fibre sizes, varying degrees of muscle fibre necrosis/rege-
neration, scattered opaque muscle fibres, proliferation, degenera-
tion, and necrosis of connective tissue, or myofibre regeneration 
(HE staining × 100)
Figure 2. Pathological analysis of immunohistochemical staining. A–D: Patients in the CON group (patients with LGMD2B): immunohisto-
chemical staining of anti-α-, b-, g-, and d- monoclonal antibodies shows the subunit proteins of sarcoglycan are expressed normally (× 500); 
E–H: patients in the SAR group (patients with LGMD2F): immunohistochemical staining of anti-α-, b-, g-, and d- monoclonal antibodies shows 
the subunit proteins of d-sarcoglycan is obviously reduced, and other subunit proteins are downregulated (× 500)
distributed and had no sparse or defective area. The overall 
function of the left ventricle was normal.
Among the 28 patients in the SAR group, the results of 
99Tcm-MIBI G-MPI were positive in 23 patients, and the po-
sitive rate was 82.1% (23/28). Two hundred and twenty-nine 
subsegments with abnormal lesions were detected from the 
391 subsegments of these 23 patients. According to the distri-
bution of intra-myocardial radioactivity, the radionuclide 
distribution slightly decreased in 88 subsegments (1 point, 
38.4%), moderately decreased in 73 subsegments (2 points, 
31.9%), severely decreased in 50 subsegments (3 points, 
21.8%), and no radioactivity distribution in 18 subsegments 
(4 points, 7.9%). According to the number of involved sites, 
among the 229 diseased subsegments, 41 subsegments were 
located at the apex, 39 subsegments were located at the an-
terior wall, 32 subsegments were located at the anterolateral 
wall, 28 subsegments were located at the inferolateral wall, 
31 subsegments were located at the inferior wall, 33 subseg-
ments were located at the inferior interarticular wall, and 
25 subsegments were located at the anterior interarticular 
wall. Six cases exhibited abnormality in two wall segments 
(mild, 8.7%), two cases exhibited abnormality in three or 
more wall segments (medium, 26.1%), and 15 cases showed 
scattered lesion distribution (severe, 65.2%) (the typical cases 
are shown in Figure 3).
Left ventricular functional parameters
In the CON group, LVEF was 56.3 ± 3.2%, EDV was 96.7 ± 
7.2 ml, and ESV was 40.4 ± 6.4 ml. Among the 23 patients that 
exhibited positive results with myocardial perfusion imaging, 
seven patients showed elevated left ventricular EDV and ESV 
(EDV 132.3 ± 11.7 ml, ESV 74.6 ± 9.6 ml), and four patients 
showed decreased LVEF 42.8 ± 2.3% with poor coordination of 
diffuse movement of the left ventricular wall (Fig. 4 for typical 
cases). The five patients with negative results of myocardial 
perfusion imaging showed normal LVEF, EDV, and ESV.
Discussion
Sarcoglycanopathy is a hereditary skeletal muscle disease 
with progressive aggravated amyosthenia and myatrophy as 
the main clinical manifestations, which gradually aggravates 
with the prolongation of the disease course. Amyosthenia and 
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Figure 3. Gated myocardial perfusion tomography reveals that the thickness of left ventricle myocardium is not uniform, and the radio-
activity distributes sparsely in the cardiac apex, anterior wall close to the apex segment, mid-anterior wall, inferior interarticular wall, and 
inferolateral wall
Figure 4. Gated myocardial perfusion tomography reveals EDV = 146 ml
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myatrophy usually become apparent in the first or second 
decades. Progressive aggravated amyosthenia makes actions 
become more difficult, together with gradually developed 
and aggravated myocardial damage as the disease progresses. 
This will seriously affect the quality of life of the patient and 
place heavy economic and social burdens upon individuals, 
families, and society. Therefore, early detection, necessary 
interventions, and dynamic observation of the prognosis of 
myocardial lesions are crucial [12–14].
At present, there are a few studies on cardiac diseases 
caused by sarcoglycanopathy [15], which are mostly detected 
using electrocardiograms and colour ultrasound. Studies 
have reported that the myocardium can be affected by sarco-
glycanopathy, and sometimes appears as dilated cardiomy-
opathy in echocardiography [15]. Studies using99Tcm-MIBI 
G-MPI in evaluating myocardiac damage in patients with 
sarcoglycanopathy are rare. In this study, 99Tcm-MIBI G-MPI 
was performed on patients clinically diagnosed with sarco-
glycanopathy, aiming to explore preliminarily the diagnostic 
value of this technique on myocardial lesions in patients with 
sarcoglycanopathy.
Of the 28 patients enrolled in this study, 23 patients 
exhibited positive results. The histological features of the 
myocardium are similar to those of skeletal muscles, as both 
are striated muscles and contain sarcolemmal proteins. In the 
case of sarcoglycanopathy, α-, b-, g-, and d-sarcoglycan form 
a sarcoglycan complex in the dystrophin glycoprotein com-
plex, which is important in stabilising the cytoskeleton of the 
muscle and has the function of maintaining the cell membrane 
stability. The loss of any of these functions can result in the 
attenuation and disappearance of the complex protein on the 
cell membrane. The defect of one component of the complex 
causes the obstruction of the synthesis and assembly process 
of other proteins on the sarcolemmal membrane, which may 
impair the integrity and stability of the sarcolemma structure, 
followed by the degeneration and necrosis of muscular cells 
[16]. The myocardial uptake of 99Tcm-MIBI is closely related to 
the integrity of the myocardial cell membrane [17], which in 
turn affects the uptake of 99Tcm-MIBI by the cardiac myocytes, 
resulting in abnormal changes such as sparseness. The defect 
in the complex protein may be an important pathogenic factor 
for sarcoglycanopathy combined with cardiomyopathy.
The degeneration and necrosis of cardiomyocytes in pa-
tients with sarcoglycanopathy occur and disperse in multiple 
sites. The characteristic of its myocardial perfusion imaging 
appears to be scattered multiple focal lesions (mostly mul-
tilaminar myocardial involvement), patchy myocardium, 
and non-segmental (having nothing to do with the shape 
of the coronary artery, and different from coronary artery 
stenosis-resulted myocardial ischaemia in the coronary artery-
-dominating area). 99Tcm-MIBI imaging can objectively reflect 
whether the myocardial cell function is normal [17]. Therefore, 
this study can objectively reflect myocardial ischaemia caused 
by paediatric coronary artery disease. The changes in cardiac 
function found in this study focused on patients with multi-
-wall lesions; the severity of myocardial damage as well as the 
state of cardiac function may be related to the extent and the 
course of such pathological changes as in myofibre necrosis 
and connective tissue hyperplasia.
Among the 28 patients, five exhibited negative results with 
99Tcm-MIBI G-MPI. The explanation may be that recent studies 
have found that sarcoglycan has other subunits, namely ε and 
ζ-sarcoglycan. These two subunits are mainly found in the smo-
oth muscle but distribute only in small amounts in the skeletal 
muscle [18]. The defective subunit protein of sarcoglycanopathy 
determines the degree of involvement of myocardial lesions. If 
the defective subunit protein is predominantly distributed in 
the skeletal muscle but in a small amount in the myocardium, 
an obvious defect of this subunit protein may be found in the 
skeletal muscle by immunohistochemical staining while my-
ocardial damage may be milder. This may be determined by the 
subunit protein. With the differences in the subunit proteins, 
the clinical phenotypes may be different. Politano et al. [19] 
performed electrocardiography, echocardiography, and pulmo-
nary function assessments on 20 patients with sarcoglycano-
pathy and found that 31.3% of the patients had normal cardiac 
function, 43.7% had subclinical myocardium disease, 6.3% 
of patients had arrhythmia myocardium disease, and 18.7% 
showed dilated cardiomyopathy. Hypoxic myocardial damage 
occurring at β, γ, and δ, and γ and δ normally shows changes 
in the dilated cardiomyopathy. Fayssoil et al. [20] compared the 
cardiac function data of eight patients with α-type sarcoglyca-
nopathy and that of 11 patients with γ-type sarcoglycanopathy 
using echocardiography, and found that the cardiac function 
in patients with γ-type sarcoglycanopathy is more vulnerable 
compared to that of patients with α-type sarcoglycanopathy 
(LVEF: 45.6 ± 1.8% vs. 59.6 ± 5.9%, P = 0.018). In addition, it 
may be related to the course of the disease to certain extent.
In this study, the positive rate of 99Tcm-MIBI G-MPI was 
82.1%. This inspection method is safe, non-invasive, and re-
peatable. The limitations of this study are that the results were 
affected by the types of disease, and the number of cases was 
limited. Our future studies will gradually increase the case 
number. Some hereditary and metabolic skeletal muscle dise-
ases involve the myocardium and are relatively invisible in the 
early stages. Late-stage revealing is one of the most important 
causes of death in such patients. When the pathological chan-
ges of the skeletal muscle are involved, myocardial involvement 
should not be spared. 99Tcm-MIBI gated myocardial perfusion 
tomography can dynamically show myocardial lesions, thus 
providing as early diagnosis and intervention as possible so 
as to improve the survival of such patients. The 99Tcm-MIBI 
myocardial rest imaging can visually show the location, extent, 
and degree of the diseased myocardium, thus providing great 
help for the judgment of clinical condition. Therefore, as a rou-
tine, simple, non-invasive, and high-diagnostic method, it has 
a high value, which can be used not only for early diagnosis of 
myocardial injury, but also for long-term follow-up studies.
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